Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach, Joshua D; Luxkaranayagam, Anita T; Dhruva, Sanket S; Miller, Jennifer E; Ross, Joseph S

Wallach, Joshua D; Luxkaranayagam, Anita T; Dhruva, Sanket S; Miller, Jennifer E; Ross, Joseph S.

Afiliación

Wallach JD; Department of Environmental Health Sciences, Yale School of Public Health, 60 College Street, 4th Floor, Room 411, New Haven, CT, 06510, USA. Joshua.wallach@yale.edu.
Luxkaranayagam AT; Collaboration for Research Integrity and Transparency (CRIT), Yale Law School, 157 Church Street, 17th Floor, Suite 1, New Haven, CT, 06510, USA. Joshua.wallach@yale.edu.
Dhruva SS; Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Hospital, 1 Church Street, Suite 200, New Haven, CT, 06510, USA. Joshua.wallach@yale.edu.
Miller JE; Collaboration for Research Integrity and Transparency (CRIT), Yale Law School, 157 Church Street, 17th Floor, Suite 1, New Haven, CT, 06510, USA.
Ross JS; University of Connecticut, Storrs, CT, 06269, USA.

BMC Med ; 17(1): 117, 2019 06 17.

Article en En | MEDLINE | ID: mdl-31203816

Asunto(s)

Aprobación de Drogas/métodos; United States Food and Drug Administration/normas; Estudios Transversales; Humanos; Estados Unidos

Palabras clave

FDA; Lifecycle evaluation; Pharmaceutical regulation; Postmarketing commitments; Postmarketing requirements

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Aprobación de Drogas Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: BMC Med Asunto de la revista: MEDICINA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google